CALENDAR OF REPORTING DATES FOR FLORIDA SPECIAL ELECTIONS—Continued

Report	Close of books ¹	Reg./Cert. & overnight mailing deadline	Filing deadline
If Two Elections Are Held, PACs and Party Committees Not Filing Monthly Involved in Only the Special General (04/01/2025) Must File:			
Pre-General	03/12/2025 04/21/2025 06/30/2025	03/17/2025 05/01/2025 07/31/2025	03/20/2025 05/01/2025 07/31/2025
If One Election Is Held, Candidate Committees Involved in the	e Special General ((01/28/2025) Must File	:
Pre-General & Year-End ³ Post-General April Quarterly	01/08/2025 02/17/2025 03/31/2025	01/13/2025 02/27/2025 04/15/2025	01/16/2025 02/27/2025 04/15/2025
If One Election Is Held, PACs and Party Committees Not Filing Monthly In	nvolved in the Spec	ial General (01/28/20	25) Must File:
Pre-General & Year-End ³ Post-General Mid-Year	01/08/2025 02/17/2025 06/30/2025	01/13/2025 02/27/2025 07/31/2025	01/16/2025 02/27/2025 07/31/2025

¹The reporting period always begins the day after the closing date of the last report filed. If the committee is new and has not previously filed a report, the first report must cover all activity that occurred before the committee registered as a political committee up through the close of books for the first report due.

Dated: December 3, 2024. On behalf of the Commission.

Sean J. Cooksey.

Chairman, Federal Election Commission. [FR Doc. 2024-28771 Filed 12-6-24; 8:45 am] BILLING CODE 6715-01-P

FEDERAL ELECTION COMMISSION

Sunshine Act Meetings

TIME AND DATE: Thursday, December 12, 2024, 10:00 a.m.

PLACE: Hybrid meeting: 1050 First Street NE, Washington, DC (12TH Floor) and virtual.

Note: If you would like to virtually access the meeting, see the instructions below.

STATUS: This meeting will be open to the public. To access the meeting virtually, go to the Commission's website www.fec.gov and click on the banner to be taken to the meeting page.

MATTERS TO BE CONSIDERED:

Draft Advisory Opinion 2024–15: Unified Libertarians of Massachusetts MUR 1604 (Brady Campaign to Prevent Gun Violence, et al): Recommendation to Relieve the Brady

Campaign from a Remedial Measure in a Conciliation Agreement

REG 2024-06 (Request to Modify or Redact Contributor Info)—Draft Notice of Proposed Rulemaking Draft Legislative Recommendations 2024

Sample LLC Donor Form Recommendation That the Office of General Counsel Conduct a Review of the Agency's Regulations

Proposed Revisions to Directives 10 (Rules of Procedure of the Federal Election Commission Pursuant to 2 U.S.C. 437(c)(e)) and 17 (Circulation Authority; Agenda Deadline Procedures)

Election of Officers for 2025 Management and Administrative Matters

CONTACT PERSON FOR MORE INFORMATION: Judith Ingram, Press Officer, Telephone: (202)694-1220.

Individuals who plan to attend in person and who require special assistance, such as sign language interpretation or other reasonable accommodations, should contact Laura E. Sinram, Secretary and Clerk, at (202) 694-1040 or secretary@fec.gov, at least 72 hours prior to the meeting date.

(Authority: Government in the Sunshine Act, 5 U.S.C. 552b)

Laura E. Sinram,

Secretary and Clerk of the Commission. [FR Doc. 2024-28995 Filed 12-5-24; 4:15 pm]

BILLING CODE 6715-01-P

FEDERAL MEDIATION AND **CONCILIATION SERVICE**

Succession Plan for the Federal **Mediation and Conciliation Service**

AGENCY: Federal Mediation and Conciliation Service (FMCS).

ACTION: Notice of succession plan for the FMCS.

SUMMARY: The Federal Mediation and Conciliation Service (FMCS) is issuing this notice to inform the public of the succession plan for the Federal Mediation and Conciliation Service (FMCS) provided by the Director of FMCS. This notice supersedes all prior succession plans issued by the agency for officials performing the functions and duties of the Director of FMCS.

DATES: This succession plan for the FMCS is effective December 9, 2024.

FOR FURTHER INFORMATION CONTACT: For specific questions related to this notice, please contact Greg Goldstein, 202-606-8111, ggoldstein@fmcs.gov.

SUPPLEMENTARY INFORMATION: By the authority vested in the Director of the Federal Mediation and Conciliation Service (FMCS) by 29 U.S.C. 172, and to provide for the continuity of essential operations of the FMCS in all circumstances this Notice provides the succession plan of officials authorized to perform the functions and duties of the Director of the Federal Mediation and Conciliation Service. The following is the succession plan of officials hereby ordered:

Order of Succession

During any period in which the Director has died, resigned, or otherwise become unable to perform the functions and duties of the office of the Director, and there is no Acting Director serving under the Federal Vacancies Reform Act of 1998, 5 U.S.C. 3345-3349d, the following officers of the FMCS, in the order listed, are hereby delegated the authority to perform the functions and duties of the Director, to the extent permitted by law:

ONS IN the list report use.

2 Committees should file a consolidated Pre-Primary & Year-End Report by the filing deadline of the Pre-Primary Report.

3 Committees should file a consolidated Pre-General & Year-End Report by the filing deadline of the Pre-General Report (if primary not held).

- 1. Principal Deputy, Chief Operating Officer:
- 2. Deputy Director, Field Operations;
- 3. Deputy Director for Labor Policy and Communications;
- 4. Director, Procurement and Operational Support;
 - 5. General Counsel;
- 6. Associate Deputy Director for Field Operations, National;
- 7. Associate Deputy Director for Field Operations, Regional;
 - 8. Director, Human Resources; and
 - 9. Director, Budget.

No individual who is serving in an office listed in this order in an acting capacity, by virtue of so serving, shall be delegated the functions and duties of the Director.

Dated: December 4, 2024.

Gregory Goldstein,

Chief Operating Officer Performing the Duties of the Director.

[FR Doc. 2024–28847 Filed 12–6–24; 8:45 am]

BILLING CODE 6732-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Agency for Healthcare Research and Quality

Supplemental Evidence and Data Request on Medical Care for Adults With Down Syndrome

AGENCY: Agency for Healthcare Research and Quality (AHRQ), HHS.

ACTION: Request for supplemental evidence and data submission.

SUMMARY: The Agency for Healthcare Research and Quality (AHRQ) is seeking scientific information submissions from the public. Scientific information is being solicited to inform our review on *Medical Care for Adults with Down Syndrome*, which is currently being conducted by the AHRQ's Evidence-based Practice Centers (EPC) Program. Access to published and unpublished pertinent scientific information will improve the quality of this review.

DATES: Submission Deadline on or before January 8, 2025.

ADDRESSES:

Email submissions: epc@ ahrq.hhs.gov.

Print submissions:

Mailing Address: Center for Evidence and Practice Improvement, Agency for Healthcare Research and Quality, ATTN: EPC SEADs Coordinator, 5600 Fishers Lane Mail Stop 06E53A, Rockville, MD 20857 Shipping Address (FedEx, UPS, etc.): Center for Evidence and Practice Improvement, Agency for Healthcare Research and Quality, ATTN: EPC SEADs Coordinator, 5600 Fishers Lane, Mail Stop 06E77D, Rockville, MD

FOR FURTHER INFORMATION CONTACT:

Kelly Carper, telephone: 301–427–1656 or email: epc@ahrq.hhs.gov.

SUPPLEMENTARY INFORMATION: The Agency for Healthcare Research and Quality has commissioned the Evidence-based Practice Centers (EPC) Program to complete a review of the evidence for *Medical Care for Adults with Down Syndrome*. AHRQ is conducting this review pursuant to section 902 of the Public Health Service Act, 42 U.S.C. 299a.

The EPC Program is dedicated to identifying as many studies as possible that are relevant to the questions for each of its reviews. In order to do so, we are supplementing the usual manual and electronic database searches of the literature by requesting information from the public (e.g., details of studies conducted). We are looking for studies that report on Medical Care for Adults with Down Syndrome. The entire research protocol is available online at: https://effectivehealthcare.ahrq.gov/products/care-adults-down-syndrome/protocol.

This is to notify the public that the EPC Program would find the following information on *Medical Care for Adults with Down Syndrome* helpful:

- A list of completed studies that your organization has sponsored for this topic. In the list, please *indicate* whether results are available on ClinicalTrials.gov along with the ClinicalTrials.gov trial number.
- For completed studies that do not have results on ClinicalTrials.gov, a summary, including the following elements, if relevant: study number, study period, design, methodology, indication and diagnosis, proper use instructions, inclusion and exclusion criteria, primary and secondary outcomes, baseline characteristics, number of patients screened/eligible/enrolled/lost to follow-up/withdrawn/analyzed, effectiveness/efficacy, and safety results.
- A list of ongoing studies that your organization has sponsored for this topic. In the list, please provide the ClinicalTrials.gov trial number or, if the trial is not registered, the protocol for the study including, if relevant, a study number, the study period, design,

- methodology, indication and diagnosis, proper use instructions, inclusion and exclusion criteria, and primary and secondary outcomes.
- Description of whether the above studies constitute *ALL Phase II and above clinical trials* sponsored by your organization for this topic and an index outlining the relevant information in each submitted file.

Your contribution is very beneficial to the Program. Materials submitted must be publicly available or able to be made public. Materials that are considered confidential; marketing materials; study types not included in the review; or information on topics not included in the review cannot be used by the EPC Program. This is a voluntary request for information, and all costs for complying with this request must be borne by the submitter.

The draft of this review will be posted on AHRQ's EPC Program website and available for public comment for a period of 4 weeks. If you would like to be notified when the draft is posted, please sign up for the email list at: https://effectivehealthcare.ahrq.gov/email-updates.

The review will answer the following questions. This information is provided as background. AHRQ is not requesting that the public provide answers to these questions.

Key Questions (KQ)

- 1. What are the benefits, harms, and considerations of screening and diagnostic interventions, for co-occurring medical and behavioral health conditions in adults with Down syndrome?
- 2. What are the benefits and harms, and considerations of interventions to treat co-occurring medical and behavioral health conditions specifically in adults with Down syndrome?

Contextual Questions (CQ)

- 1. What conditions occur at an increased or decreased prevalence in adults with Down syndrome compared to the general adult population. How does prevalence vary by age/decade of age, gender, setting (rural), and race/ethnicity?
- 2. How do clinical symptoms and the presentation of common co-occurring behavioral/mental health conditions (e.g., anxiety and depression) differ among adults with Down syndrome compared to their presentation in the general adult population?